Immorta Bio has been selected for the 2026-27 Life Sciences cohort at NYU Stern's Endless Frontier Labs, a nine-month, non-equity program for early-stage science startups. The company is developing a senolytic immunotherapy intended to restore immune clearance of senescent cells and a regenerative cell-therapy platform, and says it expects to enter human clinical development during the program. The selection reflects an assessment of scientific and commercial strategy by outside evaluators, not clinical validation.
Key Points
- Immorta Bio joins NYU Stern's Endless Frontier Labs life sciences cohort
- SenoMune aims to restore immune clearance of senescent cells
- Company expects first human clinical development during nine-month program
Longevity Analysis
Senescent cell accumulation sits at the intersection of immune surveillance and tissue repair, and restoring the body's own capacity to recognize and remove these cells is a different proposition from pharmacologically forcing their death. The company's premise — that oncology, organ failure and age-related decline share upstream mechanisms — is testable only in patients, and the absence of a named indication, trial design or timeline marks the boundary between strategy and evidence. For clinicians tracking this field, the signal worth following is the first registered protocol, not the accelerator placement.
Original published by Longevity.Technology, by Kyle Umipig.